Emerging drugs in lung transplantation

Area of Science:

• Immunology
• Transplantation Medicine
• Pharmacology

Background:

• Lung transplantation requires careful immunosuppression to balance graft tolerance with infection prevention.
• Beyond infections, malignancies and drug toxicities significantly impact patient outcomes.
• Current immunosuppression combines drugs for synergistic effects and reduced toxicity.

Purpose of the Study:

• To review current and emerging immunosuppressive therapeutic regimens in lung transplantation.
• To highlight strategies for managing complications like graft failure, acute, and chronic rejection.

Main Methods:

• Literature review of current and emerging immunosuppressive strategies.
• Analysis of therapeutic regimens for induction and maintenance phases.
• Discussion of drug combinations and their impact on toxicity and efficacy.

Main Results:

• Primary graft failure, acute, and chronic rejection are significant post-transplant complications.
• Acute rejection often responds to intensified immunosuppression.
• Chronic rejection remains a leading cause of mortality beyond the first year.

Conclusions:

• Optimizing immunosuppression is vital for long-term lung transplant success.
• Emerging drugs show promise in mitigating graft function loss.
• A comprehensive approach is needed to manage immunosuppression-related toxicities and complications.